VC-backed Lyell Immunopharma raises $425m for IPO
Lyell Immunopharma, a T-cell reprogramming company, has raised about $425 million for its IPO after pricing its 25 million shares at $17 per share.
Lyell Immunopharma, a T-cell reprogramming company, has raised about $425 million for its IPO after pricing its 25 million shares at $17 per share.
Copyright PEI Media
Not for publication, email or dissemination